Skip to Content

Strategic Prevention Framework for Presciption Drug Misuse

In 2016, NJ DMHAS was awarded the Strategic Prevention Framework for Prescription Drug Misuse (SPF-Rx) state grant from SAMHSA. The NJ SPF-Rx initiative expands interagency sharing of the state’s prescription drug monitoring program data and gives DMHAS the capability to use data analytics to identify prescribers, prescriber groups, and patients at high risk for inappropriate prescribing and nonmedical use of opioid drugs. Informed by the data, DMHAS and its prevention partners will strategically target communities and populations needing services, education or other interventions. DMHAS has recently begun receiving de-identified data from the New Jersey Prescription Monitoring Program (NJPMP), SPF-Rx will move towards a more PMP data-driven approach as a result of this project. The target population is youth (ages 12-17) and adults (18 years of age and older) who are being prescribed opioid pain medications, controlled drugs, or HCG, and are at risk for their nonmedical use.

Part of NJ’s efforts will focus on young athletes, since this population may be more likely than non-athletes to receive prescription pain medication for sports related injuries. DMHAS will conduct epidemiological analysis on the NJPMP data and employ geographic information systems (GIS) to identify communities and issues that require targeted interventions and public health initiatives. DMHAS’ Regional Prevention Coalitions will obtain data reports that will inform their planning in local communities. These reports will also be the basis for a public awareness campaign and for training of providers and the health care community on addictions and the risks of opioid prescribing. DMHAS will work with its state and community partners in promoting evidence-based practices on the prescribing opioid analgesics. DMHAS and its partners will use plans to implement soon to be released recommendations of a state workgroup, the Pain Management Council, which will be incorporating the CDC Guideline for Prescribing Opioids for Chronic Pain. Medical practitioners and pharmacies will also be involved in efforts to promote awareness of naloxone and its availability. SAMHSA’s Overdose Prevention Toolkit will be used to educate at risk individuals and their families in strategies to prevent opioid overdoses.

Back to top